Cantor Fitzgerald Comments on Verona Pharma FY2026 Earnings

Verona Pharma plc (NASDAQ:VRNA - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Verona Pharma in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer forecasts that the company will earn $12.56 per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $100.00 price target on the stock. The consensus estimate for Verona Pharma's current full-year earnings is ($1.95) per share.

Verona Pharma (NASDAQ:VRNA - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.49. The firm had revenue of $98.65 million during the quarter, compared to the consensus estimate of $41.47 million.

A number of other equities analysts also recently issued reports on the company. Jefferies Financial Group increased their price objective on Verona Pharma from $95.00 to $110.00 and gave the stock a "buy" rating in a report on Wednesday. Wells Fargo & Company increased their price objective on Verona Pharma from $93.00 to $107.00 and gave the stock an "overweight" rating in a report on Wednesday, April 30th. Roth Capital set a $83.00 target price on Verona Pharma in a research note on Friday, February 28th. HC Wainwright increased their target price on Verona Pharma from $85.00 to $90.00 and gave the stock a "buy" rating in a research note on Monday, June 2nd. Finally, TD Cowen assumed coverage on Verona Pharma in a research note on Monday, April 28th. They issued a "buy" rating and a $100.00 target price on the stock. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $87.44.

Verona Pharma Stock Down 0.3%

VRNA traded down $0.30 during trading on Wednesday, reaching $92.20. The stock had a trading volume of 754,182 shares, compared to its average volume of 1,324,026. The stock's 50 day moving average is $71.08 and its two-hundred day moving average is $60.40. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $7.48 billion, a price-to-earnings ratio of -48.02 and a beta of 0.21. Verona Pharma has a one year low of $14.14 and a one year high of $93.74.

Insider Activity at Verona Pharma

In related news, General Counsel Andrew Fisher sold 26,072 shares of the stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $8.98, for a total transaction of $234,126.56. Following the sale, the general counsel now directly owns 359,993 shares of the company's stock, valued at $3,232,737.14. This trade represents a 6.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Mark W. Hahn sold 400,000 shares of the stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $11.40, for a total value of $4,560,000.00. Following the sale, the chief financial officer now directly owns 12,278,992 shares in the company, valued at $139,980,508.80. This trade represents a 3.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,885,800 shares of company stock valued at $19,134,481 over the last ninety days. Insiders own 4.80% of the company's stock.

Institutional Investors Weigh In On Verona Pharma

Institutional investors have recently modified their holdings of the business. NBC Securities Inc. purchased a new stake in shares of Verona Pharma during the first quarter valued at $34,000. Geneos Wealth Management Inc. boosted its position in Verona Pharma by 44.2% in the first quarter. Geneos Wealth Management Inc. now owns 630 shares of the company's stock worth $40,000 after purchasing an additional 193 shares during the last quarter. Acadian Asset Management LLC purchased a new position in Verona Pharma in the first quarter worth about $48,000. NewEdge Advisors LLC purchased a new position in Verona Pharma in the first quarter worth about $58,000. Finally, Vermillion Wealth Management Inc. purchased a new position in Verona Pharma in the fourth quarter worth about $46,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.